Provided by Tiger Trade Technology Pte. Ltd.

Ocular Therapeutix

10.62
-0.8500-7.41%
Post-market: 10.830.2100+1.98%19:30 EDT
Volume:2.39M
Turnover:25.74M
Market Cap:2.32B
PE:-7.51
High:11.43
Open:11.43
Low:10.54
Close:11.47
52wk High:16.44
52wk Low:6.23
Shares:218.91M
Float Shares:185.00M
Volume Ratio:1.08
T/O Rate:1.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4140
EPS(LYR):-1.4203
ROE:-72.99%
ROA:-34.95%
PB:4.47
PE(LYR):-7.48

Loading ...

Ocular Therapeutix (OCUL) Prepares New AXPAXLI Data, Is The Stock Still Below Fair Value?

Simply Wall St.
·
Sep 03

Ocular Therapeutix Joins Baird Global Healthcare Conference Fireside Chat

Reuters
·
Sep 01

Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences

GlobeNewswire
·
Sep 01

Ocular Therapeutix (OCUL) Could Be 60% Below Fair Value As Axpaxli Story Builds

Simply Wall St.
·
Aug 25

Ocular Therapeutix Earns Buy Rating as Axpaxli Differentiation and LUGANO TKI Data Bolster Confidence in Lead Asset

TIPRANKS
·
Aug 17

Ocular Therapeutix rises 10.4%

TIPRANKS
·
Aug 17

Rival Ocular Therapeutix Shares up 8%

THOMSON REUTERS
·
Aug 17

Ocular Therapeutix Shares up 12.7% Premarket After Rival EyePoint's Eye Drug Misses Main Goal in Late-Stage Trial

THOMSON REUTERS
·
Aug 17

Ocular Therapeutix Grants New SVP Beth Rada Options for 85,000 Shares, 28,000 RSUs Under Inducement Plan

Reuters
·
Aug 14

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 14

Ocular Therapeutix Grants Inducement Awards to New Hires, Including Options Priced at $8.4 Per Share

Reuters
·
Aug 08

Ocular Therapeutix™ Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 08

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 08

Tarsus Pharmaceuticals Q2 Sales Beat Estimates, Lifts 2026 Xdemvy Sales Outlook

Reuters
·
Aug 06

Viridian Therapeutics Q2 Net Loss Widens as Lumvoa Launch Lifts Costs

Reuters
·
Aug 06

RxSight Q2 Adjusted Loss Beats Estimates; Withdraws 2026 Guidance

Reuters
·
Aug 06

Sight Sciences Q2 Revenue Rises 20%, Beats Estimates

Reuters
·
Aug 06

Canada's Kits Eyecare Q2 Revenue Slightly Beats on Glasses Segment Growth

Reuters
·
Aug 05

EyePoint Pharmaceuticals Q2 Revenue Drops on Lower License Income

Reuters
·
Aug 05

Ocular Therapeutix's NDA Plans for Axpaxli in Wet AMD Remain on Track, RBC Says

MT Newswires Live
·
Aug 04